Your Health, We Care
On February 15, 2024, the FDA approved tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) carrying a skipping mutation in exon 14 of mesenchymal epithelial transition factor (MET).
The VISION study aims to evaluate the efficacy and safety of tepotinib as a monotherapy for advanced or metastatic NSCLC patients carrying METex14 skipping mutations.
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
